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Abstract The aim of this study was to evaluate the clinical,
therapeutic, laboratory, and radiological differences between
respiratory syncytial virus (RSV) and non-RSV bronchiolitis
in order to assess if the prior knowledge of viral etiology
changed management decisions and would be able to predict
outcomes. Medical charts of children <1 year admitted to the
emergency department with bronchiolitis during two RSV
seasons (2010–2012) were reviewed. We analyzed 221 epi-
sodes of bronchiolitis. The percentage of exams performed
(95 % confidence interval (CI) 0.74–2.52), abnormal labora-
tory and radiological findings (95 % CI 0.53–16.89) did not
differ between groups. RSV bronchiolitis had a more severe
clinical course. However, virologic testing for RSV had low
specificity in identifying at-risk patients for hospitalization,
longer hospital length of stay, and need of oxygen therapy and
nasogastric tube (44, 40, 42, and 35 %, respectively), and
while statistically significant, the positive likelihood ratios
were only slightly greater than 1. Conclusion: Although
RSV bronchiolitis has a more severe clinical course, virologic
testing does not help in management decisions, and at an
individual level, as a performance test, it seems insufficient
to precisely predict outcomes.
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ICD International Classification of Diseases
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PCR Polymerase chain reaction
RSV Respiratory syncytial virus
SD Standard deviation
SpO2 Pulse oxygen saturation
WBC White blood cell
Introduction
Bronchiolitis is the most frequent cause of pediatric hospital
admissions during the winter months in early childhood, with
respiratory syncytial virus (RSV) being the causative organ-
ism in most cases; the proportion of RSV and non-RSV
bronchiolitis changes from year to year [1]. It is a major
problem of public health, causing 3.4 million hospitalizations
and between 66,000 and 199,000 deaths annually, globally, at
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an estimated annual cost of more than $700 million per year
[1, 12].
The clinical course of a child with bronchiolitis is variable,
and the potential for disease progression has led to research to
identify risk factors whose presence may indicate a severe
form of disease ormay be predictive of complications and life-
threatening, thus help physicians in the emergency department
(ED) [13, 14].
Research on prediction of the clinical course of bronchiol-
itis has revealed comorbidities and young age as important
risk factors for developing severe disease and specific physi-
cal findings as less predictive of outcomes for the majority of
cases [1, 5, 16]. During the last decade, a better understanding
of bronchiolitis etiology and the emergence of more advanced
techniques for viral detection have raised the question of
the relevance of the etiologic agent in the course of the
disease [8, 15].
Several studies have investigated whether the infection
etiology contributes to the bronchiolitis severity and have
advocated that the RSVepisodes are more severe, in contrast
to some other viruses as the human metapneumovirus
(hMPV) which affects older infants and probably has a milder
course [2, 6–8]. However, the majority of these studies only
compared the severity of different etiologic groups but did not
assess whether the prior knowledge gained from such testing
could change management decisions or predict outcomes.
Moreover, bronchiolitis guidelines advocate that the clinical
relevance of identifying the specific etiology of a child with
severe disease is still uncertain [18].
In this study, we evaluated the clinical, therapeutic,
laboratory, and radiological differences between RSV and
non-RSV bronchiolitis in order to assess if the prior knowl-
edge of the viral etiology in the ED led to changes in the
routine management and would be able to predict outcomes
in these patients.
Materials and methods
Study design and subjects
This was a retrospective, observational study during two
consecutive RSV seasons (2010–2012). We included infants
(<1 year of age) admitted to the ED of the University Hospital
of Geneva with a diagnosis of acute bronchiolitis. Patients
with chronic diseases such as congenital heart disease,
bronchopulmonary dysplasia, trisomy 21, congenital or ac-
quired immunodeficiencies, and neuromuscular disorders or
without a viral test (detection of RSV) were excluded.
Episodes of acute bronchiolitis were identified via
International Classification of Diseases (ICD), version 2010,
with the following discharge codes: acute bronchiolitis (J21),
RSV bronchiolitis (J21.0), and acute unspecified bronchiolitis
(J21.9). After reviewing the medical records, only children
who had the typical clinical presentation with rhinitis,
tachypnea, wheezing, cough, crackles, use of accessory mus-
cles, and/or nasal flaring were included [1]. This study was
approved by the institution’s ethical committee on clinical
research in children (protocol 12-026).
Data collection
Variables of interest were identified from previous studies
[16], and medical charts were reviewed for the following data:
demographic and epidemiologic (age, gender, gestational age,
and date of admission); underlying medical conditions; bac-
terial coinfections (sepsis, acute otitis media, pneumonia, and
urinary tract infection); radiological (chest X-ray) and labora-
tory tests (detection of RSV, C-reactive protein (CRP), com-
plete blood count (CBC), and capillary blood gas analysis
(pCO2 and pH)); medications received (inhaled β-receptor
agonist, systemic steroids, and antibiotics); and disease sever-
ity parameters (mortality, hospitalization, hospital length of
stay (LOS), intensive care unit (ICU) admission, requirement
and duration of nasogastric tube (NGT), supplemental oxy-
gen, and mechanical ventilation).
Regarding the laboratory and radiologic data, only tests
including CBC and CRP, capillary blood gas analysis, and
chest X-ray performed during the first 12, 6, and 24 h of
admission, respectively, were included. For blood analysis,
we considered abnormal laboratory values as pCO2 >6 kPa,
pH <7.35 or >7.45, CRP >10 mg/L, and WBC <4.5 or
>10 g/L.
Respiratory samples were collected by nasopharyngeal
aspiration during the first hour in the ED and then stored;
normally, virologic testing was performed for all hospitalized
patients during the RSV season and otherwise in some cases
for children at risk of hospitalization. The viral diagnostic tests
used included the QuickVue® RSV test (enzyme-linked
immunoassay) and/or individual one-step real-time
Taqman©-based polymerase chain reaction (PCR) or reverse
transcription PCR, as routinely performed in our virology
laboratory.
To precisely calculate the LOS, we used the ED triage
time and the hospital discharge order time. Clinical data at
presentation to the ED were noted, including the duration of
symptoms, respiratory rate, presence of wheeze, clinical
assessment of degree of retractions (assembled for analysis
into none/mild versus moderate/severe), pulse oxygen sat-
uration (SpO2), and the presence of feeding difficulties,
cyanosis, and apnea.
Standards of care
Criteria of hospitalization used in our hospital were those
published by Barben et al. [3]: children feeding less than
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50 % of the required amount, SpO2 of <92 % in air, progres-
sive respiratory failure, apnea, bradycardia, and poor social
conditions.
Infants were nourished via NGT when intake was below
50 % of normal or when excessive work of breathing was
noted. Supplemental oxygen was administered (through nasal
cannulae) for SpO2 of <92 % in air. Following recommenda-
tions of bronchiolitis guidelines [1], sometimes especially in
patients older than 6 months, a trial of inhaled β-receptor
agonist treatment was attempted in the ED. The treatment
was continued only after a proven benefit such as increase in
SpO2 and decrease of respiratory rate and wheezing. Oral
steroids were not routinely used, and finally, antibiotics were
administered when concomitant bacterial infection was
suspected. Oxygen therapy was stopped once values for
SpO2 in air were ≥92 %. SpO2 monitoring was continuous
(Philips model M3 oximeter), with a 10-h observation period
after removal before discharge.
Statistics
Results are presented as mean ± standard deviation (SD) or
median with interquartile range (IQR) for continuous vari-
ables and as percentages for categorical variables.
Continuous variables were analyzed using Student’s t test
or Mann-Whitney test and categorical variables by the χ2
test or Fischer’s exact test, as appropriate, and the 95 %
confidence interval (CI) for odds ratio (OR) was deter-
mined according to standard methods. A P value <0.05
was considered statistically significant. All the analyses
were performed by using Stata 12.0 (StataCorp, College
Station, TX, USA).
To evaluate the differences in clinical course and disease
severity between children with RSVand non-RSV bronchiol-
itis, we compared rates of hospitalization, longer LOS
(>3 days; defined using the median value of 3 days), supple-
mental oxygen (including invasive and noninvasive ventila-
tion) and NGT requirements, longer duration of oxygen ther-
apy (>2 days; defined using the median value of 2 days),
longer duration of NGT (>3 days; defined using the median
value of 3 days), ICU admission, reconsultation after dis-
charge, and mortality.
Diagnostic accuracy statistics including sensitivity, speci-
ficity, and positive and negative likelihood ratios (LR+ and
LR−) were calculated for variables of disease severity that
were statistically different between the RSV and non-RSV
groups.
We retrospectively calculated the power and for the first
outcomes (hospital length of stay, need of oxygen therapy and
NGT), using the sample size of 221 episodes, gave 85.7–
99.6 % power to detect differences between the two groups,
with a 0.05 two-sided significance level.
Results
Study group
There were 479 infants (582 episodes) under 1 year and
without chronic diseases presenting to the ED with bronchi-
olitis. In contrast to the literature [18], we had 184/582 (32 %)
of hospitalizations considering all the patients with the diag-
nosis of bronchiolitis visiting the ED in the study period. In
our study, we included 202 patients (123 M, 79 F) and 221
episodes of bronchiolitis in which viral diagnostic tests were
performed, 157 being RSV positive and 64 negative (non-
RSV). There was a mean of 1.1±0.34 episodes per patient
(range, 1–3). Themean age was 4.57±3.4 months (range, 0.3–
11.8). Patients with RSV bronchiolitis were younger than non-
RSV patients (4.2±3.4 vs. 5.4±3.3 months, P=0.0231).
Figure 1 shows the monthly distribution of episodes of bron-
chiolitis during the seasons 2010/2012.
Emergency department presentation
ED presentation among the groups is shown in Table 1. The
groups did not differ with respect to the initial clinical presen-
tation. The frequency of comorbidities such as pneumonia,
sepsis, acute otitis media, and urinary tract infection also did
not differ between the groups.
Medications received
The medications received are summarized in Table 2. The
medications used during the week leading up to the ED visit
and the medications received at discharge did not differ be-
tween the groups. As opposed to medical recommendations
against the excessive use of a bronchodilator in bronchiolitis
treatment [18], we found a high percentage of patients who
received inhaled β-receptor agonist treatment in both groups.
Patients with RSVepisodes were less likely to receive inhaled
β-receptor agonist treatment at the hospital (95 % CI 0.24–
0.80). We also analyzed the patients who had received inhaled
β-receptor agonist treatment before arriving at the ED and if
the treatment was stopped in the hospital; we found no statis-
tical difference between RSV and non-RSV groups (95 % CI
0.17–1.72).
Laboratory tests and radiological findings
The laboratory or radiological exams were performed in 84
(38 %) episodes, and the number of exams did not differ
between the groups (95 % CI 0.74–2.52). Among children
who had capillary blood analysis (blood gas (57 samples),
CBC (35 samples), and CRP (35 samples)), the groups did not
differ with respect to abnormal levels of pCO2 (95 % CI 0.9–
23.14) and pH (95 % CI 0.22–4.26), white blood cell (WBC)
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count (95 % CI 0.05–1.82), and CRP (95 % 0.41–10.52). A
chest radiograph was performed in 54 (24 %) episodes, and
the radiological pattern most commonly described for both
groups was the presence of bronchial wall thickening/
hyperinflation followed by focal opacity and atelectasis. The
two groups also did not differ with respect to the percentage of
abnormal chest radiographic findings (95 % CI 0.53–16.89).
Differences in clinical course and disease severity
between RSVand non-RSV bronchiolitis
The median LOS, duration of oxygen therapy, and duration of
NGT for all episodes were 3 days (IQR 1.5–5.1), 2 days (IQR
1.2–3.8), and 3 days (IQR 1.7–4.5), respectively. Compared to
the non-RSV group, the RSV group had higher rates of
hospitalization and longer LOS and duration of oxygen
therapy. The number of children who required supplemental
oxygen and NGT was also higher for children with RSV
bronchiolitis (Table 3). These results remained significant
even when the OR was adjusted for age.
To avoid bias related to our criteria of hospitalization, we
analyzed the rates of oxygen therapy and NGT only in hospi-
talized children; the higher rates of oxygen therapy in the RSV
group remained statistically significant (86 vs. 67 %,
P=0.007), and there was also a nearly significant trend toward
higher rates of NGT (51 vs. 35 %, P=0.06) in this group. We
documented no deaths.
Subanalysis in patients under 3 and 6 months
We performed a subanalysis in patients under 3 and 6 months,
and the results were similar, except for the percentage of
Fig. 1 Monthly distribution of bronchiolitis episodes during the study period (2010–2012)
Table 1 Characteristics of the episodes in the emergency department: RSV versus non-RSV bronchiolitis
RSV (n=157) Non-RSV (n=64) OR (95 % CI) P value
Age of <3 months, % 49 33 1.97 (1.07–3.62) 0.029
Female gender, % 41 33 1.40 (0.76–2.59) 0.27
Duration of symptoms at presentation, mean±SD, days 2.78±2.06 2.71±2.05 n.a. 0.83
Respiratory rate higher than normal for age, %a 76 80 0.79 (0.39–1.62) 0.53
Retractions moderate/severe, % 69 73 0.82 (0.42–1.57) 0.55
Presence of wheeze, % 39 44 0.83 (0.46–1.51) 0.59
Oxygen saturation at arrival in ED, mean±SD, %b 94.92±4.47 94.26±7.04 n.a. 0.40
Presence of bacterial coinfections, %
Sepsis 1 0 n.a. n.a.
Pneumonia associated 9 3 3.03 (0.67–13.75) 0.15
Acute otitis media associated 16 13 1.32 (0.56–3.11) 0.52
Urinary tract infection associated 2 0 n.a. n.a.
RSV respiratory syncytial virus, ED emergency department, OR odds ratio, CI confidence interval, SD standard deviation, n.a. not analyzed
a Normal values for age groups were as follows: 0 to 1.9 months of age, 45 breaths per minute; 2 to 5.9 months of age, 43 breaths per minute; 6 to
11.9 months of age, 40 breaths per minute
b In room air
1432 Eur J Pediatr (2014) 173:1429–1435
patients who received inhaled β-receptor agonist treatment at
the hospital in patients <6 months. Although in this age group
<6 months, RSV episodes were also less likely to receive
inhaled β-receptor agonist treatment at the hospital; the dif-
ferences between groups were not significant (13 and 22% for
RSVand non-RSV group, respectively, P=0.18).
Accuracy of the virologic testing for RSV in detecting
outcomes in patients with bronchiolitis
Table 4 shows the sensitivity, specificity, and positive and
negative likelihood ratios with the following 95 % CI of
virologic testing for RSV in detecting at-risk patients for
hospitalization, longer LOS, need and longer duration of
oxygen therapy, and need of NGT. Among patients admitted
at the ED with a diagnosis of bronchiolitis, the virologic
testing for RSV had low specificity in detecting outcomes
for all analyzed variables, and the positive LRs were slightly
greater than 1.
Discussion
In agreement with previous reports [6, 7], patients with RSV
bronchiolitis were younger and male was the predominant
gender. In this study, the groups did not differ with respect
to the initial clinical presentation. Different from us,
Bamberger et al. found that children with RSV had a more
severe initial clinical presentation compared to those with
non-RSV bronchiolitis [2].
Previous studies have identified that RSV patients were
more likely to receive systemic corticosteroids [7] and that
patients hospitalized with bronchiolitis were more likely to
receive inhaled β-receptor agonist and antibiotics at the hos-
pital [9]. In these studies, the authors suggested that clinicians
used more treatments for sicker children, with the hope of
some benefits, although recent recommendations and guide-
lines do not encourage this attitude as it does not shorten the
natural course of bronchiolitis [4, 18].
Even though our study was not designed to investigate the
effectiveness of specific treatments in patients with bronchi-
olitis, we found that children with RSV episodes were less
likely to receive inhaled β agonist at the hospital. However,
interestingly, the groups did not differ with respect to the
number of children who had received inhaled β-receptor
agonist treatment before arriving at the ED and continued to










Medication used during the past week, %
Inhaled β-receptor
agonist treatment
24 34 0.59 (0.31–1.10) 0.10
Oral corticosteroids 1.9 1.6 1.22 (0.12–12.02) 0.86
Antibiotics 8 5 1.83 (0.50–6.67) 0.36
Medication received in the hospital, %
Inhaled β-receptor
agonist treatment
28 47 0.44 (0.24–0.80) 0.008
Oral corticosteroids 4 3 1.44 (0.29–7.15) 0.65
Antibiotics 12 8 1.62 (0.57–4.55) 0.36
Medication received at discharge, %
Inhaled β-receptor
agonist treatment
9 11 0.79 (0.30–2.07) 0.64
Oral corticosteroids 0 0 n.a. n.a.
Antibiotics 16 13 1.32 (0.56–3.11) 0.52
RSV respiratory syncytial virus, OR odds ratio, CI confidence interval,
n.a. not analyzed
Table 3 Differences in clinical course and disease severity between RSVand non-RSV bronchiolitis
RSV (n=157) Non-RSV (n=64) OR (95 % CI) P value aOR (95 % CI) P value
Hospitalization in ward/ICU, % 83 67 2.46 (1.26–4.81) 0.008 2.17 (1.09–4.32) 0.03
Hospitalization in ICU, % 7.6 7.8 0.97 (0.32–2.89) 0.97 n.a. n.a.
LOS of >3 days, % 61 36 2.73 (1.49–4.98) 0.001 2.45 (1.32–4.54) 0.004
Oxygen therapy, % 72 48 2.73 (1.49–4.98) 0.001 2.78 (1.51–5.13) 0.001
Duration of oxygen therapy of >2 days, %a 60 29 3.69 (1.55–8.74) 0.003 3.15 (1.30–7.62) 0.01
Noninvasive ventilation, % 7 5 1.53 (0.41–5.68) 0.52 n.a. n.a.
Intubated, % 0.6 0 n.a. n.a. n.a. n.a.
Nasogastric tube, % 44 23 2.56 (1.32–4.94) 0.005 2.14 (1.07–4.29) 0.03
Duration of NGT of >3 days, %b 45 40 1.22 (0.39–3.81) 0.73 n.a. n.a.
Reconsultation after ED discharge, % 12 8 1.62 (0.57–4.55) 0.36 n.a. n.a.
RSV respiratory syncytial virus, ICU intensive care unit, ED emergency department, LOS hospital length of stay, NGT nasogastric tube, OR odds ratio,
aOR odds ratio adjusted for age, CI confidence interval, n.a. not analyzed
a Among 144 patients who needed oxygen therapy
bAmong 84 patients who needed a nasogastric tube
Eur J Pediatr (2014) 173:1429–1435 1433
receive it in the hospital. The result of the RSV test was not
known by the clinicians when treatment decisions were taken
in the ED. Therefore, we assume that the management in the
ED was not modified due to viral etiology. Furthermore, both
groups showed no difference in initial clinical presentation at
the ED; thus, we believe that disease severity also did not
influence doctors’ decision in ED. Unfortunately, it was not
possible to evaluate whether previous knowledge of virus
etiology influenced management decisions in the ward or
whether the higher rates of inhaled β-receptor agonist in the
non-RSV group were due to a better response in this group.
Even though we performed less exams compared to other
studies, it is still important to question whether we are
performing more radiographs than necessary as this may
increase the amount of abnormal radiographic findings and
the unnecessary use of antibiotics. In previous studies, where
more chest radiographs were performed (88 % of patients), a
significantly higher proportion of focal opacities and atelecta-
sis in the RSV group was found [6, 7]. In a randomized trial,
children with suspected lower respiratory tract infection
who underwent chest radiographs received more antibi-
otics without any difference in time until recovery [17]. It
is also reported that about 25 % of hospitalized children
with bronchiolitis will have radiographic evidence of atel-
ectasis or infiltrates, often misinterpreted as possible bac-
terial infection [1].
Our findings are consistent with those of previous studies
that found that RSV patients had longer LOS [2, 6, 7, 10, 11]
and were more likely to have more supplemental oxygen
requirements [6, 7] and inadequate oral intake [2, 7, 10].
However, these studies did not evaluate the duration of
NGT, and only one reported a significantly longer dura-
tion of oxygen therapy in RSV patients compared to non-
RSV [11].
In our study, we aimed to evaluate the accuracy of virologic
testing for RSV in detecting patients at risk for a more severe
disease. We found that even though the group of children
admitted with RSV bronchiolitis had a more severe clinical
course, virologic testing at an individual level did not have
good accuracy in identifying patients at risk for hospitaliza-
tion, longer LOS, and higher oxygen and NGT requirements,
certainly because there are many other variables involved in
disease severity and not only the viral etiology. While statis-
tically significant, the positive LRs that we found were only
slightly greater than 1. The low specificity values showed that
we could increase the costs by performing viral tests only for
prognosis proposal in about 60 % of patients who would not
have a prolonged stay and would not even be hospitalized.
Our study has potential limitations; it has a retrospective
design, and we limited the identification of patients in the
ICD, which may have underestimated the number of patients
with bronchiolitis. We also included patients with more than
one episode of bronchiolitis, and even though some investi-
gators emphasize the importance of looking at bronchiolitis in
only those without prior wheeze illness, this is not a consensus
and heterogeneity in the population exists [18]. Our sampling
of patients probably presents a greater disease severity as we
included only the patients in which viral tests had been per-
formed. Indeed, in our routine hospital protocol, the majority
of tests are performed in hospitalized patients for room isola-
tion procedure. This also explains the high rates of hospitali-
zation we had in this group. However, the same type of bias
can be applied to both groups, which makes the data set
comparable; moreover, our main outcomes were factors that
can be evaluated mainly in hospitalized patients.
Following bronchiolitis guidelines, saying that virologic
testing for RSV obtained during peak RSV season demon-
strates a high predictive value for the diagnosis [1], the viral
diagnostic tests were performed mainly during the RSV sea-
son. For this reason, the detection of RSV was not uniform
during the 2 years of retrospective study. However, in the
months when RSV tests were not routinely performed, the
incidence of all bronchiolitis episodes was low, which sug-
gests that we did not lose many cases of RSVepisodes due to
lack of sample collection in the off-season periods (see Fig. 1).
Besides, a very small proportion of non-RSV cases may also
represent RSV infections that were not detected due to a false-
negative assay result. Another limitation is that we did not
analyze other viruses and the possible coinfections; therefore,
categorizing children only by the RSV status alone may have
obfuscated real associations which are described in some
studies [11].
Table 4 Sensitivity, specificity, and likelihood ratios of virologic testing for RSV in detecting at-risk patients for more severe disease (n=221)
Sensitivity (95 % CI)
[range]
Specificity (95 % CI)
[range]
Positive LR (95 % CI)
[range]
Negative LR (95 % CI)
[range]
Hospitalization 75 (68–81) 44 (31–59) 1.4 (1.0–1.8) 0.5 (0.4–0.8)
LOS of >3 days 80 (72–87) 40 (31–49) 1.3 (1.1–1.6) 0.5 (0.3–0.7)
Needed oxygen therapy 78 (71–84) 42 (32–54) 1.4 (1.1–1.7) 0.5 (0.3–0.7)
Duration of oxygen therapy of >2 days 88 (79–93) 33 (23–45) 1.3 (1.1–1.6) 0.4 (0.2–0.7)
Needed nasogastric tube 82 (72–89) 35 (28–44) 1.3 (1.1–1.5) 0.5 (0.3–0.8)
RSV respiratory syncytial virus, LR likelihood ratio, LOS hospital length of stay, CI confidence interval
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In conclusion, etiologic diagnosis is mainly useful for
cohorting patients and for infection control especially in hos-
pitalized patients. RSV-positive patients have a heavier eco-
nomical impact; indeed, our study and other studies have
shown that these patients have generally longer LOS and
higher oxygen therapy and NGT requirements [2, 6, 7, 10,
11]. However, different from other studies, our study indicates
that at an individual level, as a performance test, virologic
testing alone seems insufficient to precisely predict the out-
comes. Therefore, virologic testing should not be routinely
done in all patients presenting at the ED because it does not
predict outcomes or help in management decisions as it may
increase costs without adding further information. These find-
ings would benefit from additional validation and analysis in
prospective studies.
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